AMF Medical Receives FDA Breakthrough Device Designation for Its Sigitm Insulin Management System

ECUBLENS, Switzerland, Nov. 30, 2021 /PRNewswire/ -- AMF Medical is proud to announce that its Sigitm Insulin Management System, for diabetes mellitus treatment, has met the criteria and has been granted Breakthrough Device Designation by the US Food and Drug Administration.

Sigitm can be programmed to deliver basal and bolus insulin at both set and variable rates. In addition, as an Alternate Controller Enabled-pump, it is able to receive, execute and confirm dosing commands by interacting with Bluetooth-compatible, continuous glucose monitors and alternate controller devices, like a smartphone or an iController.

Sigitm is also smaller, lighter and more convenient than current insulin delivery systems. This is made possible by its ergonomic design, which accommodates standard, insulin pre-filled pump cartridges.

AMF Medical Co-CEO and Co-Founder Mr. Antoine Barraud said: "We would like to thank the FDA for recognizing our team's proprietary, patient-focused technology, which provides users with enhanced clinical and convenience features. This Breakthrough Device Designation will expedite the development of Sigitm and prioritize its review in future FDA regulatory submissions. It is a huge step forward in bringing Sigitm to market to improve insulin management."

"Clinical study data has shown that Sigitm is delightfully easy to use. Study patients have expressed satisfaction as well as eagerness for this next generation patch to be readily available. We are pleased that the FDA also sees its clear value and is moving the process forward," said Professor A. Wojtusciszyn, MD, PhD from Lausanne University Hospital (CHUV) and principal investigator of the first Sigitm clinical study.

About AMF Medical

Originally founded in 2014 in the Swiss Medtech Valley, AMF Medical is developing a novel technology to address the unmet needs of people on insulin therapy. The company's flagship product, Sigitm, is a next-generation, plug 'n go, semi-reusable and rechargeable patch pump, designed to make life easier for people with diabetes. Sigitm is intended for prescription-use only and not yet FDA Cleared nor CE-marked. AMF Medical is led by Co-CEOs Mr. Pim van Wesel and Mr. Antoine Barraud, PhD who is also a Co-Founder. Diabetes industry experts John Timberlake and Peter Gerhardsson serve on the company's Board of Directors.

Click here and scroll down to watch a video to learn how Sigi works.
For more information, please visit: https://sigipump.com.
Follow us on LinkedIn.

Video - https://youtu.be/Vkh_HWQF2os

Company Contact:
Estelle Sabau
Office Manager
AMF Medical SA
+41-21-552 3670
[email protected]

Press Contact:
Marjie Hadad
General Manager
Must Have Communications
+1-917-790-1178
[email protected]

SOURCE AMF Medical